Diabetes

Drug Makers Vie for Insulin Market Share, Patients Wait for Relief

August 12th 2017

By Kelly Davio

Price competition in the US insulin market is heating up; Novo Nordisk reported in its second-quarter earnings call that its 2018 US insulin prices could drop below 2017 levels.

Eye on Pharma: Biocon's Profits Drop by 51% Despite Strong Insulin Sales

July 31st 2017

By The Center for Biosimilars Staff

Biocon’s net profits for the past quarter dropped by 51%, according to a statement made by the Bangalore-based drug manufacturer.

A Look at the Regulatory Process for Approval of Biosimilar Insulins in Europe

July 29th 2017

By Jackie Syrop

The emergence of biosimilar insulins may help broaden access to modern insulins, increase individualized treatment options, and reduce the cost of insulin therapy. Yet many healthcare providers may not understand the concept of biosimilarity and how biosimilar medications are similar, not identical, to their reference products.

Merck Wins Tentative FDA Approval of Follow-on Insulin Glargine

July 21st 2017

By Kelly Davio

The FDA has granted Merck’s insulin glargine (Lusduna Nexvue) tentative approval. Merck says that its follow-on basal insulin has met all required regulatory standards of clinical and nonclinical safety, efficacy, and quality for follow-on biologics.

Nevada Governor Signs Insulin Price Transparency Bill, Strictest in Nation

June 16th 2017

By Jackie Syrop

Republican Nevada Governor Brian Sandoval yesterday signed into law the country’s strictest requirements for drug companies to show how they set prices for certain prescription drugs, with a specific focus on insulin.

Biosimilar Insulin Glargine Shows Pharmacokinetic and Pharmacodynamic Equivalence to the Originator

June 15th 2017

By Jackie Syrop

The study pesented at the American Diabetes Association 77th Scientific Sessions compared Mylan/Biocon’s MYL-1501D, a proposed biosimilar to Sanofi-Aventis’ insulin glargine, with the reference product.

Study Finds Significant Differences in Glycemic Control Between Reference and Biosimilar Morning Insulin

June 14th 2017

By Kelly Davio

In order to investigate the best morning insulin therapy to improve glycemic variability in patients with type 2 diabetes, researchers from Japan compared morning injections of insulin glulisine and insulin glargine with injections of insulin lispro and insulin glargine biosimilar.

New Bill in Nevada Spotlights Ambiguity in Insulin Pricing

May 24th 2017

By Jackie Syrop

EMA Recommends Approval of Sanofi's Insulin Lispro Biosimilar

May 22nd 2017

By Jackie Syrop